Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
We read with great interest the review article written by Jiang t al. [1] on the role of circulating tumor DNA (ctDNA) analysis n non small cell lung cancer (NSCLC) They discussed the clinial applications of ctDNA in patient management. It is now clear hat EGFR alterations can be detected in patients' ctDNA before 2 4] and during [5 7] tyrosine kinase inhibitor (TKI) treatment. etection of the T790M resistance mutation, a common molecular echanism of acquired resistance to firstand second generation KIs [8,9] is of particular interest since third generation TKIs ave shown favorable results in patients presenting this mutation
Lung cancer